Used in the treatment of acute myeloid leukemia (AML), this antibody targets CD123, a marker overexpressed on leukemic stem cells. It helps the immune system identify and destroy cancer cells. Investigated in clinical trials for its ability to induce responses in relapsed or refractory AML patients. Also explored in myelodysplastic syndromes and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Works through mechanisms like antibody-dependent cellular cytotoxicity (ADCC) and direct signaling inhibition.